Cancer pill makeover may mess with treatment adherence

NCT ID NCT07664683

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 334 cancer patients to see if switching between different-looking generic chemo pills affects their adherence and health outcomes. Researchers will track pill counts and patient surveys over six months. The goal is to understand if changes in pill color, shape, or packaging cause confusion or missed doses, and to inform better policies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

oral antineoplastics (chemotherapy pills)

What this could lead to

If successful, this could lead to policies that keep pill appearance consistent, helping cancer patients stay on track with their treatment.

What could go wrong

This is an observational study, not testing a new drug. Results may not apply to all cancer types or settings, and adherence is hard to measure accurately.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm Patient Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Universidad Miguel Hernández

    RECRUITING

    San Juan, Alicante, 03550, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••